Rosiglitazone (BRL), a PPARγ agonist used in type 2 diabetes treatment, has been shown to inhibit CXCR4 expression and to reduce the malignancy in colon, lung and prostate cancer cells [40–42]. Here, CXCR4 is linked to prostate carcinoma.